The interrelated fields of immunology and inflammation are positioned for a blockbuster 2022 after a 2021 marred by a US FDA review of safety in the massive Janus kinase inhibitor space and ongoing difficulties in conducting manufacturing inspections during the COVID-19 pandemic.
The year is off to a strong start, with 14 January approvals of two atopic dermatitis (eczema) therapies that hold...








